ClinicalTrials.gg
RecruitingNCT07734792TOPAZUpdated Nov 12, 2026

Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

A Phase 2/3 interventional study of Tirzepatide and Standard Medical Care (SMC) in Acute Ischemic Stroke (AIS), sponsored by yifang zhu. Recruiting at 1 site in China. Open to participants aged 19 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by yifang zhu · Phase 2/3, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 12, 2026Now RecruitingStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
726
Allocation
Randomized
Ages
19 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 754 studies in Ischemic Stroke with a site in China — 381 open to participants now, 400 under way, 78 of them phase 3. Ischemic Stroke · China.

Planned enrollment
142nd of 566
726 · median 271
Started
2026
with 124 others
Phase 2/3
25 of 754
9 open now
Primary completion
2028-05
later than 310 of 399 live
Registered
714th of 754
by date

Among the 754 studies in Ischemic Stroke with a site in China, this one is the 142nd largest by planned enrollment of the 566 interventional ones that give a count, is one of 125 that started in 2026, is one of 25 in phase 2/3, reaches primary completion later than 310 of the 399 other live ones, and was the 714th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

381 of the 754 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

375 more — sign in →

All 381 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 19 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 754 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

Acute ischemic stroke caused by blockage of a large artery in the brain is one of the leading causes of death and long-term disability worldwide. For patients with this type of stroke, endovascular thrombectomy (EVT), a procedure that removes the blood clot and restores blood flow to the brain, has become the standard treatment. However, even when blood flow is successfully restored, many patients continue to experience disability because of ongoing brain injury caused by inflammation, oxidative stress, and damage to brain cells after the stroke.

This study aims to evaluate whether tirzepatide, a medication that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) pathways, can improve recovery in patients with acute ischemic stroke caused by large vessel occlusion who receive thrombectomy. Tirzepatide is currently approved for the treatment of conditions such as type 2 diabetes and obesity. Previous studies have shown that tirzepatide can improve blood sugar control, reduce body weight, and provide beneficial effects on cardiovascular health. Laboratory studies and early clinical evidence suggest that medications targeting GLP-1 and GIP pathways may also have protective effects on the brain by reducing inflammation, protecting brain cells, improving blood vessel function, and supporting recovery after stroke.

In this study, eligible patients with acute ischemic stroke caused by blockage of a major brain artery will be randomly assigned to receive either tirzepatide plus standard stroke care or standard stroke care alone. Participants will receive two subcutaneous injections of tirzepatide: the first dose before the thrombectomy procedure and the second dose 7 days after the procedure. The study will include multiple hospitals and will use independent assessment of outcomes to ensure reliable evaluation of treatment effects.

The primary purpose of this study is to determine whether early treatment with tirzepatide can improve functional recovery 90 days after stroke, measured by the patient's ability to perform daily activities and live independently. The study will also evaluate whether tirzepatide is safe in patients with acute ischemic stroke by monitoring adverse events, complications, and other clinical outcomes.

The findings from this study may provide important evidence for a new treatment approach to improve recovery after thrombectomy and reduce disability among patients with severe ischemic stroke.

Read the detailed description

1.1 Stroke Burden Approximately 2.4 million new stroke cases occur annually in China, resulting in about 1.1 million deaths each year. More than 11 million people are currently living with stroke, and the incidence, prevalence, and mortality rates continue to rise, with an increasing trend toward younger age groups. Stroke has become the leading cause of death and disability in China, imposing a substantial burden on patients, families, and society as a whole.

Among all stroke subtypes, acute ischemic stroke (AIS) accounts for approximately 70%-80% of cases. Patients with concomitant large vessel occlusion (LVO) experience the most severe neurological deficits. Although some patients are eligible for intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA), only 26.5% achieved functional independence at 90 days, while the 90-day mortality rate remains as high as 18.9%, making AIS-LVO one of the greatest challenges in stroke management.

1.2 Endovascular thrombectomy in patients with large vessel occlusion The cornerstone of treatment for acute ischemic stroke with large vessel occlusion (AIS-LVO) is rapid recanalization of the occluded artery to salvage the ischemic penumbra. Since 2015, five landmark randomized controlled trials (RCTs), including MR CLEAN, EXTEND-IA, and SWIFT PRIME, published in The New England Journal of Medicine, have demonstrated the efficacy of endovascular thrombectomy (EVT) in patients with AIS-LVO, representing a revolutionary breakthrough in stroke care.

Subsequently, a pooled meta-analysis published in The Lancet in 2016 showed that EVT achieved a 90-day favorable functional outcome rate of 46.0%, representing a 2.71-fold increase compared with standard medical therapy, further confirming the substantial clinical benefit of thrombectomy.

The DAWN and DEFUSE 3 trials further extended the EVT treatment window to 24 hours after symptom onset. These studies demonstrated that, among carefully selected patients with salvageable ischemic penumbra identified by advanced imaging, EVT significantly improved clinical outcomes even when performed 6-24 hours after stroke onset. More recently, the BAOCHE and ATTENTION trials extended the proven benefits of EVT to posterior circulation stroke. Consequently, EVT has received the highest level of recommendation in international stroke guidelines.

To promote stroke prevention and treatment, the National Health Commission of China established the National Stroke Prevention and Control Committee, aiming to advance and expand access to evidence-based stroke interventions, including EVT. Early thrombectomy during the acute phase of stroke plays a critical role in reducing disability and mortality, thereby alleviating the societal burden of stroke.

1.3 Factors influencing outcomes after reperfusion therapy Although approximately 90% of patients achieve successful reperfusion (mTICI 2c-3) following EVT, only 40%-45% attain favorable functional outcomes at 90 days. Nearly half of patients remain severely disabled or die despite successful recanalization.

Recent studies have identified multiple factors associated with poor outcomes after reperfusion therapy, including advanced age, multiple comorbidities, poor collateral circulation, distal microthrombosis and microvascular dysfunction, stress hyperglycemia, inflammatory responses, oxidative stress, hemorrhagic transformation, and cerebral edema. Therefore, interventions targeting multiple pathophysiological pathways may further improve outcomes following EVT.

Several studies have investigated strategies aimed at improving microcirculatory dysfunction, reducing inflammation, and providing neuroprotection before or after thrombectomy. Some of these studies have demonstrated promising neuroprotective effects and improved clinical outcomes.

1.4 Neuroprotective effects of GLP-1/GIP dual receptor agonists after stroke Glucagon-like peptide-1 (GLP-1) receptors are widely expressed in pancreatic β-cells, the heart, vasculature, kidneys, immune cells, and the central nervous system. GLP-1 receptor agonists exert glucose-lowering and metabolic regulatory effects through multiple mechanisms, including enhancement of glucose-dependent insulin secretion, improvement of insulin resistance, suppression of chronic inflammation, modulation of lipid metabolism, and promotion of weight loss.

Importantly, GLP-1 receptor agonists can cross the blood-brain barrier (BBB) and directly act on the central nervous system. Their neuroprotective effects include inhibition of neuronal apoptosis, suppression of neuroinflammation, reduction of oxidative stress, preservation of mitochondrial function, enhancement of synaptic plasticity and cognition, and protection of cerebral vasculature and the neurovascular unit.

Experimental studies using middle cerebral artery occlusion (MCAO) models in diabetic db/db mice have demonstrated that GLP-1 analogues, including exendin-4 and liraglutide, reduce oxidative stress and inflammation, improve cerebral microcirculation, and activate the p-Akt/p-eNOS signaling pathway. Exendin-4 also partially reverses MCAO-induced motor dysfunction, cognitive impairment, and urinary dysfunction.

Glucose-dependent insulinotropic polypeptide (GIP) is another major incretin hormone. GIP receptors are expressed in pancreatic β-cells, adipose tissue, the heart, vascular endothelium, immune cells, and the central nervous system. GIP receptor agonists enhance insulin secretion, promote β-cell survival, improve insulin resistance, reduce chronic inflammation, and facilitate weight control through improved lipid handling and redistribution.

Like GLP-1 receptor agonists, GIP receptor agonists can directly act on the brain, exerting anti-apoptotic, anti-inflammatory, antioxidative, and mitochondrial protective effects while preserving BBB integrity and neurovascular unit function.

Given these complementary mechanisms, GLP-1/GIP dual receptor agonists simultaneously activate both signaling pathways and may provide synergistic benefits in glycemic control and neuroprotection compared with single-receptor agonists.

A recent preclinical study investigated the role of tirzepatide in repairing BBB injury after ischemic stroke. Using both MCAO mouse models and oxygen-glucose deprivation/reoxygenation (OGD/R) cellular models, investigators demonstrated that tirzepatide improved neurological function, reduced BBB permeability, and increased expression of the tight-junction protein Claudin-1. Mechanistic analyses suggested that these effects were mediated through activation of the C/EBP-α/Claudin-1 signaling pathway, thereby maintaining BBB integrity.

Accumulating evidence indicates that GLP-1 receptor agonists have become first-line glucose-lowering agents with benefits extending beyond glycemic control. These benefits include substantial weight loss, reduced risks of coronary heart disease and stroke, and lower rates of heart failure hospitalization. Clinical studies further suggest that GLP-1/GIP dual receptor agonists achieve cardiovascular outcomes comparable to those of GLP-1 receptor agonists while providing superior glycemic control and weight reduction.

BBB disruption, hyperglycemia-related injury, neuroinflammation, oxidative stress, and neuronal apoptosis are recognized as major mechanisms underlying secondary brain injury after successful recanalization in AIS-LVO. Both GLP-1 and GIP receptor agonists can cross the BBB and exert multiple neuroprotective effects, including glucose lowering, anti-inflammatory and antioxidative actions, BBB preservation, inhibition of neuronal apoptosis, and enhancement of synaptic plasticity. Moreover, the two pathways may exert synergistic neuroprotective effects.

A recent randomized study involving 140 patients with AIS-LVO compared semaglutide (0.5 mg administered before thrombectomy and during the first postoperative week) with standard care. The semaglutide group achieved a 10% higher rate of excellent functional outcome (mRS 0-1) at 90 days without significant safety concerns. More recently, the GALLOP-2 trial suggested that semaglutide administered before EVT and again on day 7 after thrombectomy increased the proportion of patients achieving an excellent 90-day functional outcome by 15.3% compared with controls. These findings suggest that early administration of a GLP-1/GIP dual receptor agonist, through its comprehensive multi-target neuroprotective mechanisms, may substantially improve outcomes in patients with AIS-LVO following successful reperfusion.

Therefore, there is an urgent need for a randomized controlled trial to evaluate the efficacy and safety of early GLP-1/GIP dual receptor agonist therapy in patients with AIS-LVO after successful recanalization.

Tirzepatide, the investigational drug in the present study, is a dual GLP-1/GIP receptor agonist. Multiple high-quality randomized controlled trials have demonstrated that tirzepatide provides glycemic control and weight reduction superior or non-inferior to GLP-1 receptor agonists such as semaglutide, with an excellent safety profile. These findings have been published in leading journals including The New England Journal of Medicine, The Lancet, and JAMA. Tirzepatide is currently approved for the treatment of type 2 diabetes, obesity, and obstructive sleep apnea.

The SUMMIT trial enrolled 731 obese patients (BMI ≥30 kg/m²) with heart failure with preserved ejection fraction (HFpEF), who were randomized to tirzepatide (up to 15 mg weekly) or placebo for at least 52 weeks. Tirzepatide significantly reduced the composite endpoint of cardiovascular death or worsening heart failure (9.9% vs. 15.3%), corresponding to a 38% relative risk reduction.

Similarly, the SURMOUNT-5 trial randomized 751 adults with obesity but without type 2 diabetes to receive tirzepatide (10 or 15 mg weekly) or semaglutide (1.7 or 2.4 mg weekly) for 72 weeks. Tirzepatide demonstrated superior reductions in body weight and waist circumference.

Collectively, tirzepatide and related agents have accumulated substantial evidence supporting their efficacy and safety in populations with diabetes, obesity, heart failure, and stroke, with treatment durations extending up to 72 weeks and favorable safety profiles.

For patients with acute ischemic stroke, "time is brain," and rapid initiation of neuroprotective therapy is crucial. Starting tirzepatide at 2.5 mg and waiting four weeks before escalation to 5 mg may delay the therapeutic window. Therefore, we referenced a Phase I clinical study published in Diabetes, Obesity and Metabolism, in which patients with type 2 diabetes received tirzepatide 5 mg as the initial dose for eight weeks. No serious adverse events or treatment discontinuations due to adverse events occurred, and all adverse events were mild to moderate and reversible, supporting the acceptable safety of a 5-mg starting dose.

Based on these findings and the need for rapid therapeutic effects in acute ischemic stroke, the present study will use 5 mg as the initial dose. We propose a multicenter, randomized, controlled, blinded-endpoint trial to evaluate the efficacy and safety of two subcutaneous doses of tirzepatide in patients with anterior-circulation AIS-LVO, administered before thrombectomy and on day 7 after the procedure. This strategy has the potential to further improve functional outcomes in patients undergoing EVT for acute ischemic stroke.

03

Conditions studied

  • Acute Ischemic Stroke (AIS)

Browse trials for

Keywords

  • acute ischemic stroke
  • endovascular thrombectomy
  • large vessel occlusion
  • tirzepatide
  • GLP-1/GIP
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
19 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria:

  1. Age >18 years and ≤80 years;
  2. Acute ischemic stroke with imaging-confirmed anterior large vessel occlusion at:

    • Terminal ICA,
    • M1 segment of the middle cerebral artery, or
    • Dominant M2 segment;
  3. NIHSS score between 6 and 25 prior to randomization;
  4. Alberta Stroke Program Early CT Score (ASPECTS) of 6-10 before randomization;
  5. Time from symptom onset (or last known well) to planned endovascular thrombectomy within 24 hours;
  6. Pre-stroke mRS score of 0-1;
  7. Patients presenting within 6 hours of symptom onset are eligible for direct EVT. Patients presenting between 6 and 24 hours after symptom onset must undergo advanced imaging demonstrating a salvageable perfusion mismatch and meet the DEFUSE-3 criteria: an infarct core volume \<70 mL, a mismatch volume >15 mL, and a mismatch ratio >1.8;
  8. Written provided by the participant or a legally authorized representative.

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded:

  1. Posterior-circulation large vessel occlusion stroke;
  2. Simultaneous bilateral anterior-circulation occlusions or concurrent anterior- and posterior-circulation occlusions;
  3. Intracranial hemorrhage on baseline CT or MRI, including subarachnoid hemorrhage or intracerebral hemorrhage; evidence of large established infarction, defined as:

    • ASPECTS \<6,
    • Ischemic core volume ≥70 mL on CTP, or
    • Infarction involving >1/3 of the middle cerebral artery territory;
  4. Active bleeding within the previous month (e.g., gastrointestinal, genitourinary, or retinal hemorrhage), major organ surgery or within 14 days before stroke onset, or known bleeding diathesis;
  5. hypertension despite treatment, defined as persistent systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg;
  6. Severe hepatic or renal impairment, including:

    • Estimated (eGFR) \<30 mL/min/1.73 m²,
    • Serum creatinine >200 μmol/L,
    • Class C or higher liver disease,
    • Recurrent unexplained hypoglycemia;
  7. Blood glucose \<2.7 mmol/L or >22.2 mmol/L; count \<80 × 10⁹/L; or (INR) >1.7;
  8. Previous use of GLP-1 receptor agonists or GIP receptor agonists, or known to these agents;
  9. Personal or family history of medullary thyroid carcinoma (MTC) or diagnosis of Multiple Endocrine Neoplasia Type 2 (MEN2);
  10. History of severe anxiety or depression prior to stroke onset;
  11. Severe underlying disease with \<1 year, such as advanced ;
  12. Pregnancy or breastfeeding;
  13. Participation in another clinical trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
726 participants (estimated)

Study arms

  • Experimental
    Tirzepatide Intervention Group

    Participants will receive two subcutaneous injections of tirzepatide: the first administered before EVT and the second administered 7 days after EVT, in addition to standard medical care

    Drug: Tirzepatide · Other: Standard Medical Care (SMC)

  • Active comparator
    Control Group

    Participants will receive EVT and standard medical care without tirzepatide.

    Other: Standard Medical Care (SMC)

Interventions

  • Participants will receive two subcutaneous injections of tirzepatide (5 mg each): the first administered before EVT and the second administered 7 days after EVT, in addition to standard medical care

    Also known as: Mounjaro

  • OtherStandard Medical Care (SMC)

    Participants will receive EVT and standard medical care without tirzepatide.

06

What researchers measure

Primary outcomes

  1. The primary efficacy outcome: Proportion of patients achieving an excellent functional outcome

    A excellent functional outcome is defined as modified Rankin Scale (mRS) score of 0-1 at 90 days. The Modified Rankin Scale ranges from 0 to 6, where 0 indicates no symptoms, 1 indicates symptoms without significant disability, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe disability, 5 indicates severe disability, and 6 indicates death. Higher scores indicate worse functional outcomes.

    Time frame: 90 ± 7 days after randomization

  2. The primary safety outcome: All-cause mortality

    death from any cause within 90 days

    Time frame: 90 ± 7 days

Secondary outcomes

  1. The secondary efficacy outcome: Distribution of mRS scores at 90 days after randomization

    Ordinal Modified Rankin Scale (mRS) analysis. The Modified Rankin Scale ranges from 0 to 6, where 0 indicates no symptoms, 1 indicates symptoms without significant disability, 2 indicates slight disability, 3 indicates moderate disability, 4 indicates moderately severe disability, 5 indicates severe disability, and 6 indicates death. Higher scores indicate worse functional outcomes.

    Time frame: 90 ± 7 days

  2. The secondary efficacy outcome: Proportion of patients achieving an good functional outcome

    A good functional outcome is defined as an Modified Rankin Scale (mRS) 0-2 at 90 days after randomization.

    Time frame: 90 ± 7 days

  3. The secondary safety outcome: Symptomatic intracranial hemorrhage (sICH)

    defined by the Heidelberg Bleeding Classification within 48 hours after thrombectomy

    Time frame: within 48 hours after thrombectomy

Other outcomes

  1. Early neurological improvement

    Early neurological improvement defined as a reduction of ≥4 points in National Institutes of Health Stroke Scale (NIHSS) score from baseline to 7 days. National Institutes of Health Stroke Scale (NIHSS) score. The NIHSS ranges from 0 to 42, with 0 indicating no neurological deficit and higher scores indicating more severe neurological impairment. Higher scores indicate worse neurological outcomes.

    Time frame: 7 ± 2 Days

  2. Recanalization rate of the target LVO vessel

    Defined as the proportion of patients with successful recanalization of the target occluded vessel at 7 days after EVT or hospital discharge, whichever occurs first, among those achieving successful reperfusion after EVT (final mTICI score ≥2b).

    Time frame: at 7 days after EVT or hospital discharge

  3. Health-related quality of life

    Assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. The EQ-5D-5L assesses five health dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5-level scale ranging from 1 to 5, where 1 indicates no problems and 5 indicates extreme problems or inability to perform the activity. Higher scores indicate worse health status.

    Time frame: 90 ± 7 days

  4. Early neurological deterioration

    Early neurological deterioration defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score within 48 hours after randomization.

    Time frame: within 48 hours after randomization

  5. any intracranial hemorrhage

    any intracranial hemorrhage on CT or MRI scan

    Time frame: within 48 hours after EVT

  6. All-cause mortality within 7 days after randomization

    defined as death from any cause

    Time frame: within 7 days after randomization

  7. serious adverse events

    serious adverse events within 90 days

    Time frame: 90 ± 7 days

  8. Hypoglycemic events

    random blood glucose \<2.7 mmol/L within 7 days after randomization.

    Time frame: within 7 days after randomization

  9. Cognitive Function at 90 days

    Cognitive Function Assessed by AD8 at 90 days. The AD8 Dementia Screening Interview Score is used to assess cognitive impairment. The total score ranges from 0 to 8, with higher scores indicating greater cognitive impairment.

    Time frame: 90 ± 7 days

  10. Patient Health Questionnaire-9 (PHQ-9) score at 90 days

    Psychological Function Assessed PHQ-9 at 90 days. The Patient Health Questionnaire-9 (PHQ-9) score is used to assess depressive symptoms. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: 90 ± 7 days

  11. The Generalized Anxiety Disorder-7 (GAD-7) Score at 90 days

    Psychological Function Assessed by GAD-7 at 90 days. The Generalized Anxiety Disorder-7 (GAD-7) Score is used to assess anxiety symptoms. The total score ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms.

    Time frame: 90 ± 7 days

07

Study locations

1 of 1 sites recruiting
  • The Second Afliated Hospital of SooChow University
    Suzhou, Jiangsu 215004, China
    Recruiting
08

References and documents

Publications

  • Kruger N, Schneeweiss S, Fuse K, Matseyko S, Sreedhara SK, Hahn G, Schunkert H, Wang SV. Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction. JAMA. 2025 Oct 14;334(14):1255-1266. doi: 10.1001/jama.2025.14092. PubMed 40886075 ↗
  • Furihata K, Mimura H, Urva S, Oura T, Ohwaki K, Imaoka T. A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obes Metab. 2022 Feb;24(2):239-246. doi: 10.1111/dom.14572. Epub 2021 Nov 18. PubMed 34647404 ↗
  • Wang H, Ko H, Leung TW, Huang J, Sai J, Liang Y, Li H, Zhang J, Cao Q, Zang W, Li Y, Ma SH, Lui WT, Choi J, Chan C, Wong J, Kwok AJ, Ma K, Fan F, Chan A, Ip V, Leung H, Soo Y, Wong KT, Lai B, Chu CM, Leung HS, Hui A, Cheung T, Abrigo J, Li SH, Chan L, Yeung J, Pan S, Yip T, Lui LT, Hung T, Tsang SF, Leng X, Lam B, Mok VCT, Chan RHM, Nguyen TN, Hu W, Che F, Ip BY. Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial. Nat Commun. 2025 Dec 14;16(1):11274. doi: 10.1038/s41467-025-66167-z. PubMed 41392086 ↗
  • Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I; SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025 Mar 6;392(10):958-971. doi: 10.1056/NEJMoa2410819. Epub 2024 Nov 13. PubMed 39536238 ↗
  • Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lando L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PubMed 34170647 ↗
  • Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornoe CW, Ryan DH; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PubMed 37952131 ↗
  • Holscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. Neuropharmacology. 2018 Jul 1;136(Pt B):251-259. doi: 10.1016/j.neuropharm.2018.01.040. Epub 2018 Jan 31. PubMed 29402504 ↗
  • Wang D, Wang J, Li B, Yang S, Guo F, Zheng B, Wang J. Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-alpha pathways. Mol Med. 2025 Jul 23;31(1):263. doi: 10.1186/s10020-025-01312-4. PubMed 40702450 ↗
  • Li PC, Liu LF, Jou MJ, Wang HK. The GLP-1 receptor agonists exendin-4 and liraglutide alleviate oxidative stress and cognitive and micturition deficits induced by middle cerebral artery occlusion in diabetic mice. BMC Neurosci. 2016 Jun 13;17(1):37. doi: 10.1186/s12868-016-0272-9. PubMed 27296974 ↗
  • Goldenberg RM, Cheng AYY, Fitzpatrick T, Gilbert JD, Verma S, Hopyan JJ. Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists. Stroke. 2022 May;53(5):1813-1822. doi: 10.1161/STROKEAHA.121.038151. Epub 2022 Mar 9. PubMed 35259929 ↗
  • Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacol Res. 2022 Dec;186:106550. doi: 10.1016/j.phrs.2022.106550. Epub 2022 Nov 11. PubMed 36372278 ↗
  • Wang C, Gu H, Huo X, Yuan B, Li S, Xu J, Jiang Y, Jing J, Yao X, Li Z, Long F, Ma Z, Zhuang X, Xu L, Jin Y, Huang W, Zhang Y, Wen J, Wang A, Pan Y, Ye W, Yu W, Cheng A, Wang M, Dong Q, Xu A, Wang N, Yang Y, Meng X, Liu L, Zhao X, Li H, Miao Z, Li Z, Wang Y; TASTE-2 investigators. Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): randomised controlled trial. BMJ. 2026 Jan 7;392:e086850. doi: 10.1136/bmj-2025-086850. PubMed 41500725 ↗
  • Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, Sarraj A, Kasner SE, Ansari SA, Yeatts SD, Hamilton S, Mlynash M, Heit JJ, Zaharchuk G, Kim S, Carrozzella J, Palesch YY, Demchuk AM, Bammer R, Lavori PW, Broderick JP, Lansberg MG; DEFUSE 3 Investigators. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018 Feb 22;378(8):708-718. doi: 10.1056/NEJMoa1713973. Epub 2018 Jan 24. PubMed 29364767 ↗
  • Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, Sila CA, Hassan AE, Millan M, Levy EI, Mitchell P, Chen M, English JD, Shah QA, Silver FL, Pereira VM, Mehta BP, Baxter BW, Abraham MG, Cardona P, Veznedaroglu E, Hellinger FR, Feng L, Kirmani JF, Lopes DK, Jankowitz BT, Frankel MR, Costalat V, Vora NA, Yoo AJ, Malik AM, Furlan AJ, Rubiera M, Aghaebrahim A, Olivot JM, Tekle WG, Shields R, Graves T, Lewis RJ, Smith WS, Liebeskind DS, Saver JL, Jovin TG; DAWN Trial Investigators. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018 Jan 4;378(1):11-21. doi: 10.1056/NEJMoa1706442. Epub 2017 Nov 11. PubMed 29129157 ↗
  • Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Davalos A, Majoie CB, van der Lugt A, de Miquel MA, Donnan GA, Roos YB, Bonafe A, Jahan R, Diener HC, van den Berg LA, Levy EI, Berkhemer OA, Pereira VM, Rempel J, Millan M, Davis SM, Roy D, Thornton J, Roman LS, Ribo M, Beumer D, Stouch B, Brown S, Campbell BC, van Oostenbrugge RJ, Saver JL, Hill MD, Jovin TG; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016 Apr 23;387(10029):1723-31. doi: 10.1016/S0140-6736(16)00163-X. Epub 2016 Feb 18. PubMed 26898852 ↗
  • Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, Yan B, Dowling RJ, Parsons MW, Oxley TJ, Wu TY, Brooks M, Simpson MA, Miteff F, Levi CR, Krause M, Harrington TJ, Faulder KC, Steinfort BS, Priglinger M, Ang T, Scroop R, Barber PA, McGuinness B, Wijeratne T, Phan TG, Chong W, Chandra RV, Bladin CF, Badve M, Rice H, de Villiers L, Ma H, Desmond PM, Donnan GA, Davis SM; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 Mar 12;372(11):1009-18. doi: 10.1056/NEJMoa1414792. Epub 2015 Feb 11. PubMed 25671797 ↗
  • Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30. PubMed 31662037 ↗
  • Wu S, Wu B, Liu M, Chen Z, Wang W, Anderson CS, Sandercock P, Wang Y, Huang Y, Cui L, Pu C, Jia J, Zhang T, Liu X, Zhang S, Xie P, Fan D, Ji X, Wong KL, Wang L; China Stroke Study Collaboration. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol. 2019 Apr;18(4):394-405. doi: 10.1016/S1474-4422(18)30500-3. PubMed 30878104 ↗
  • Wang W, Jiang B, Sun H, Ru X, Sun D, Wang L, Wang L, Jiang Y, Li Y, Wang Y, Chen Z, Wu S, Zhang Y, Wang D, Wang Y, Feigin VL; NESS-China Investigators. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation. 2017 Feb 21;135(8):759-771. doi: 10.1161/CIRCULATIONAHA.116.025250. Epub 2017 Jan 4. PubMed 28052979 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for May 2028, 20 months after the start.

Of 31 phase 2/3 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 55. This study's planned 20 months is below that.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, last on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2026
First posted
Jul 29, 2026
StartActual
Sep 26, 2026was Aug 2026
Primary completionEst.
May 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
The Second Afliated Hospital of SooChow University is now Recruiting
Nov 12, 2026
Start date
Aug 10, 2026→Sep 26, 2026 (actual)
moved 2 times, Oct 1, 2026 – Nov 12, 2026
Enrollment
430→726
Oct 1, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • RemovedReceipt of intravenous thrombolysis prior to randomization;
Nov 12, 2026
Documents
Secondary outcomes
3 added
What changed in the outcomes
  • Addedother outcomeCognitive Function at 90 daysTime frame: 90 ± 7 days
  • Addedother outcomePatient Health Questionnaire-9 (PHQ-9) score at 90 daysTime frame: 90 ± 7 days
  • Addedother outcomeThe Generalized Anxiety Disorder-7 (GAD-7) Score at 90 daysTime frame: 90 ± 7 days
Oct 1, 2026
Show all 2 updates
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    The Second Afliated Hospital of SooChow University is now Recruiting
    Start date Sep 20, 2026→Sep 26, 2026 (now actual)
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • RemovedReceipt of intravenous thrombolysis prior to randomization;
    + 2 other changes: identifiers and verification date
  2. Oct 1, 2026
    Start date Aug 10, 2026→Sep 20, 2026
    Enrollment 430→726
    Secondary outcomes 3 added
    What changed in the outcomes
    • Addedother outcomeCognitive Function at 90 daysTime frame: 90 ± 7 days
    • Addedother outcomePatient Health Questionnaire-9 (PHQ-9) score at 90 daysTime frame: 90 ± 7 days
    • Addedother outcomeThe Generalized Anxiety Disorder-7 (GAD-7) Score at 90 daysTime frame: 90 ± 7 days
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07734792
Lead sponsor
yifang zhu
Responsible party
yifang zhu (Professor, Second Affiliated Hospital of Soochow University) — Sponsor-investigator
First posted
Jul 29, 2026
Start date
Sep 26, 2026
Primary completion
May 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Guodong Xiao, MD.PhD
Contact
gdxiao@suda.edu.cn
+8618020289268
Shoujiang You, MD.PhD
Contact
0319503013@163.com
+8615995738506
Guodong Xiao, MD.PhD
principal investigator · The Second Afliated Hospital of SooChow University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion